Clinical Scorecard: Pegcetacoplan Data Show Increasing Benefit Over 5 Years
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Pegcetacoplan inhibits complement-mediated retinal tissue damage, preserving retinal tissue |
| Target Population | Patients with GA secondary to AMD, including nonsubfoveal and subfoveal lesions |
| Care Setting | Ophthalmology clinical settings with capability for intravitreal injections and monitoring |
Key Highlights
- Pegcetacoplan treatment over 5 years resulted in progressive preservation of retinal tissue, saving up to 3.9 mm² (over 1.5 disc areas).
- Early initiation of pegcetacoplan treatment doubled retinal tissue preservation compared to delayed treatment.
- Treatment saved approximately 1.5 years of disease progression by 60 months with a consistent and manageable safety profile.
Guideline-Based Recommendations
Diagnosis
- Diagnose GA secondary to AMD using clinical and imaging assessments to identify lesion size and location.
Management
- Initiate pegcetacoplan treatment early to maximize retinal tissue preservation.
- Administer pegcetacoplan monthly or every other month as per clinical trial regimens.
- Consider continuous treatment for sustained benefit over 5 years.
Monitoring & Follow-up
- Monitor GA lesion growth via imaging to assess treatment efficacy.
- Observe for adverse events including intraocular inflammation and infectious endophthalmitis.
- Manage mild to moderate inflammation with topical medications as needed.
Risks
- Low rates of infectious endophthalmitis (0.04%) and intraocular inflammation (0.24%) reported.
- Rare ischemic optic neuropathy (0.02%) with no reported occlusive or nonocclusive retinitis or vasculitis.
Patient & Prescribing Data
Elderly patients with GA secondary to AMD enrolled in clinical trials OAKS, DERBY, and GALE.
Continuous pegcetacoplan treatment over 5 years preserves retinal tissue progressively and delays disease progression with a favorable safety profile.
Clinical Best Practices
- Start pegcetacoplan treatment early in the disease course to maximize tissue preservation.
- Maintain consistent dosing regimen (monthly or every other month) for sustained efficacy.
- Use projected sham lesion growth models to evaluate treatment benefit post-crossover.
- Monitor patients closely for ocular adverse events and manage promptly with topical therapies.
- Educate patients on the progressive benefits of long-term treatment and safety profile.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.